机构:[1]Department of Vascular Intervention, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University ofChinese Medicine, Zhongshan, China[2]Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College ofGuangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[3]Department of Traditional Chinese Medicine, The First AffiliatedHospital of Guangdong Pharmaceutical University, Guangzhou, China[4]Emergency Department, The First Affiliated Hospital ofSun Yat-sen University, Guangzhou, China中山大学附属第一医院[5]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China[6]Department of Traditional Chinese Medicine, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China深圳市康宁医院深圳医学信息中心中国医学科学院阜外医院深圳医院
Citrus flavanoids intake can reduce the risk of cardiovascular diseases. Naringenin, a natural predominant flavonoid abundant in citrus fruits, possesses protective effects against atherothrombotic diseases. As platelet activation plays central roles in atherothrombogenesis, we studied the effects of naringenin on platelet activation, signaling, thrombosis and hemostasis. Naringenin dose-dependently inhibited agonist-induced platelet aggregation in vitro, and exhibited more-potent efficacy on ADP-induced platelet aggregation. It also suppressed platelet aggregation stimulated by ADP ex vivo. Naringenin inhibited ADP-induced platelet alpha -granule secretion, fibrinogen binding, intracellular calcium mobilization and platelet adhesion on collagen-coated surface. Naringenin also inhibited platelet spreading on fibrinogen and clot retraction, processes mediated by outside-in integrin signaling. Mechanism studies indicated that naringenin suppressed PI3K-mediated signaling and phosphodiesterase activity in platelets, in addition to increasing cGMP levels and VASP phosphorylation at Ser239. Furthermore, naringenin-induced VASP phosphorylation and inhibition of platelet aggregation were reversed by a PKA inhibitor treatment. Interestingly, naringenin inhibited thrombus formation in the (FeCl3)-induced rat carotid arterial thrombus model, but not cause a prolonged bleeding time in mice. This study suggests that naringenin may represent a potential antiplatelet agent targeting PI3K and cyclic nucleotide signaling, with a low bleeding risk.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81403341, 81774219]; Guangzhou Science and Technology Plan project [201710010107]; Guangdong Provincial Science and Technology Plan [2016A020226,011]; Joint Innovation Specific Project in Key Areas from Guangdong Branch Institute of China Academy of Chinese Medical Sciences [ZZ0908065]; Clinical Research of Lingnan academic schools of TCM from Guangdong Provincial Hospital of Chinese Medicine [YN2014LN07]
第一作者机构:[1]Department of Vascular Intervention, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University ofChinese Medicine, Zhongshan, China[2]Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College ofGuangzhou University of Chinese Medicine, Guangzhou, China
通讯作者:
通讯机构:[2]Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College ofGuangzhou University of Chinese Medicine, Guangzhou, China[5]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
推荐引用方式(GB/T 7714):
Huang Manting,Deng Minzhen,Nie Wenqiang,et al.Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling[J].FRONTIERS IN PHARMACOLOGY.2021,12:doi:10.3389/fphar.2021.722257.
APA:
Huang, Manting,Deng, Minzhen,Nie, Wenqiang,Zou, Dezhi,Wu, Huanlin&Xu, Danping.(2021).Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling.FRONTIERS IN PHARMACOLOGY,12,
MLA:
Huang, Manting,et al."Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling".FRONTIERS IN PHARMACOLOGY 12.(2021)